Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination
Sign Up to like & getrecommendations! Published in 2022 at "Blood"
DOI: 10.1182/blood.2022016815
Abstract: Conflict of interest: COI declared see note COI notes: The authors declare no competing financial interests. MB is a consultant for Oxford Immunotech. AS is a consultant for Gritstone Bio, Flow Pharma, Arcturus Therapeutics, ImmunoScape,… read more here.
Keywords: cll sars; hybrid immunity; immunity immunocompromised; immunocompromised patients ... See more keywords